Oncotelic Therapeutics and Sapu Nano to Present at the 2025 San Antonio Breast Cancer Symposium (SABCS)

October 23, 2025 | Agoura Hills, CA — Oncotelic Therapeutics, Inc. and Sapu Nano announced that three abstracts featuring SAPU-003 Deciparticle™ Everolimus were accepted for presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS), December 9–12, 2025 in San Antonio, Texas.

Presentation Highlights

Abstracts will cover clinical rationale, biomarker signatures, and pharmacokinetics supporting SAPU-003’s ongoing First-in-Human program in HR+/HER2- metastatic breast cancer.

About SAPU-003 (Deciparticle™ Everolimus)

SAPU-003 is the first intravenous Deciparticle™ formulation of everolimus. The sub-20 nm design aims to improve tumor penetration, reduce off-target toxicity, and enhance pharmacokinetics relative to oral mTOR inhibitors.

About Sapu Nano

Sapu Nano develops sub-20 nm Deciparticle™ therapeutics for oncology and rare pediatric diseases, supported by joint venture collaboration between Oncotelic Therapeutics and Dragon Oversea.